Literature DB >> 17332507

Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow.

Dolores Baksh1, Raphael Yao, Rocky S Tuan.   

Abstract

Human umbilical cord perivascular cells (HUCPVCs) have been shown to have a high proliferative potential and the capacity to differentiate into an osteogenic phenotype. HUCPVCs have thus been considered a possible extra-embryonic mesenchymal stem cell (MSC) source for cell-based therapies. To assess this potential, we compared HUCPVCs to the "gold standard" bone marrow mesenchymal stromal cells (BMSCs) with respect to their proliferation, differentiation, and transfection capacities. HUCPVCs showed a higher proliferative potential than BMSCs and were capable of osteogenic, chondrogenic, and adipogenic differentiation. Interestingly, osteogenic differentiation of HUCPVCs proceeded more rapidly than BMSCs. Additionally, HUCPVCs expressed higher levels of CD146, a putative MSC marker, relative to BMSCs. HUCPVCs showed comparable transfection efficiency as BMSCs using a nucleofection method but were more amenable to transfection with liposomal methods (FuGENE). Gene array analysis showed that HUCPVCs also expressed Wnt signaling pathway genes that have been implicated in the regulation of MSCs. The similar characteristics between HUCPVCs and MSCs support the applicability of HUCPVCs for cell-based therapies. Disclosure of potential conflicts of interest is found at the end of this article.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17332507     DOI: 10.1634/stemcells.2006-0709

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  340 in total

1.  Stem cell-calcium phosphate constructs for bone engineering.

Authors:  H H K Xu; L Zhao; M D Weir
Journal:  J Dent Res       Date:  2010-10-06       Impact factor: 6.116

Review 2.  Molecular mediators of mesenchymal stem cell biology.

Authors:  Maria P Alfaro; Sarika Saraswati; Pampee P Young
Journal:  Vitam Horm       Date:  2011       Impact factor: 3.421

Review 3.  Umbilical cord-derived mesenchymal stem cells: strategies, challenges, and potential for cutaneous regeneration.

Authors:  Siming Yang; Sha Huang; Changjiang Feng; Xiaobing Fu
Journal:  Front Med       Date:  2012-03-31       Impact factor: 4.592

4.  In vitro analysis of mesenchymal stem cells derived from human teeth and bone marrow.

Authors:  Yuichi Tamaki; Taka Nakahara; Hiroshi Ishikawa; Soh Sato
Journal:  Odontology       Date:  2012-07-07       Impact factor: 2.634

Review 5.  Activity of mesenchymal stem cells in therapies for chronic skin wound healing.

Authors:  Austin Nuschke
Journal:  Organogenesis       Date:  2013-12-10       Impact factor: 2.500

6.  Mesenchymal progenitor cells derived from traumatized human muscle.

Authors:  W M Jackson; A B Aragon; F Djouad; Y Song; S M Koehler; L J Nesti; R S Tuan
Journal:  J Tissue Eng Regen Med       Date:  2009-02       Impact factor: 3.963

Review 7.  Adipose mesenchymal stem cells in the field of bone tissue engineering.

Authors:  Cecilia Romagnoli; Maria Luisa Brandi
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

8.  Human embryonic stem cell-derived mesenchymal stem cell seeding on calcium phosphate cement-chitosan-RGD scaffold for bone repair.

Authors:  Wenchuan Chen; Hongzhi Zhou; Michael D Weir; Minghui Tang; Chongyun Bao; Hockin H K Xu
Journal:  Tissue Eng Part A       Date:  2013-01-28       Impact factor: 3.845

Review 9.  Physical non-viral gene delivery methods for tissue engineering.

Authors:  Adam J Mellott; M Laird Forrest; Michael S Detamore
Journal:  Ann Biomed Eng       Date:  2012-10-26       Impact factor: 3.934

10.  Human bone marrow-derived mesenchymal stem cells display enhanced clonogenicity but impaired differentiation with hypoxic preconditioning.

Authors:  Lisa B Boyette; Olivia A Creasey; Lynda Guzik; Thomas Lozito; Rocky S Tuan
Journal:  Stem Cells Transl Med       Date:  2014-01-16       Impact factor: 6.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.